FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to compounds of formula , wherein: X and Y independently mean a nitrogen atom or the chain -CR4-, wherein R4 means a nitrogen atom; A means an aryl or heteroaryl group, with the above aryl or heteroaryl groups are optionally substituted by one or more groups specified in a halogen atom, a hydroxyl group, (C1-C4)alkyl group, (C3-C5)cycloalkyl group, (C1-C4)alkoxy group optionally substituted by (C1-C4)alkoxy group, a halogen alkyl group, a halogen alkoxy group; W means a halogen atom; Z means (C1-C4)alkylene group optionally substituted by one or more groups specified in a halogen atom and (C1-C4)alkyl group; B means the group -NR4R5, wherein R4 and R5 independently mean (C1-C4)alkyl group; R1 and R2 mean: - or R1 means a hydrogen atom and R2 mean (C1-C4)alkyl group, - or R1 and R2 together with a carbon atom whereto attached form a mono- or polycyclic system specified in: (C3-C8)cycloalkyl group, a bicyclic bridge group or a tetracyclic bridge group; the above system may be substituted by one or more hydroxyl groups; R3 means either the group C(O)R5, wherein R5 means (C1-C4)alkoxygroup optionally substituted by (C1-C4)alkoxygroup, or the group NR6R7, wherein R6 and R7 independently mean a hydrogen atom, (C1-C4)alkyl group, (C3-C5)cycloalkyl group, (C1-C4)alkylsulphonyl group, a halogenalkyl group, or the group -CH2XR8, wherein: - X means an oxygen atom and R8 means a hydrogen atom or (C1-C4)alkyl group, - or the nitrile group (CN); p means an integer equal to 0 or 1; the aryl group represents an aromatic monocyclic group containing 5 or 6 carbon atoms; the above cycle may be fused with a partially saturated heterocyclic group containing 5 or 6 atoms, including one or two heteroatoms, such as an oxygen atom; the heteroaryl group represents an aromatic cyclic group containing 5 or 6 atoms, including one or two heteroatoms, such as nitrogen; in the form of a base or an additive salt with an acid or base, as well as to their enantiomers and diastereoisomers, including to their racemic mixtures. Besides, the invention refers to methods for preparing the compound of formula I, as well as to a therapeutic agent and a pharmaceutical composition which possess antagonist action on an urotensin II receptor and contain the compound of formula I.
EFFECT: there are prepared and described the new compounds which possess urotensin II receptor antagonist action.
9 cl, 44 ex, 2 tbl
Title | Year | Author | Number |
---|---|---|---|
PHARMACEUTICAL AGENT CONTAINING INHIBITOR OF SODIUM-DEPENDENT PHOSPHATE CARRIER | 2015 |
|
RU2740008C2 |
PHARMACEUTICAL PRODUCT CONTAINING INHIBITOR OF SODIUM DEPENDENT PHOSPHATE CARRIER | 2015 |
|
RU2811864C1 |
ARYL-N-ARYL DERIVATIVES FOR TREATING RNA VIRAL INFECTION | 2020 |
|
RU2821414C2 |
HETEROCYCLYLAMIDOSUBSTITUTED IMIDAZOLE DERIVATIVES | 2006 |
|
RU2415851C2 |
ARYL AND HETEROARYLETHYLACTYLGUANIDINE, PREPARING AND USING THEM IN THERAPY | 2007 |
|
RU2446165C2 |
BRUTON'S TYROSINE KINASE INHIBITORS | 2010 |
|
RU2542585C2 |
USING EP4 RECEPTOR ANTAGONISTS IN TREATING IL-23-MEDIATED DISEASES | 2011 |
|
RU2571816C2 |
DERIVATIVE OF THIENOPYRAZOLE, HAVING ACTIVITY THAT INHIBITS PHOSPHODIESTERASE 7(PDE 7) | 2005 |
|
RU2376309C2 |
SELECTIVE PROTEIN KINASE INHIBITORS | 2012 |
|
RU2612972C2 |
OXYGEN-SUBSTITUTED DERIVATIVES OF 3-HETEROAROYLAMINOPROPIONIC ACIDS AND THEIR APPLICATION AS PHARMACEUTICAL SUBSTANCES | 2011 |
|
RU2561126C2 |
Authors
Dates
2013-11-10—Published
2009-02-05—Filed